1. A short interval between bevacizumab and anti-epithelial growth factor receptor therapy interferes with efficacy of subsequent anti-EGFR therapy for refractory colorectal cancer. (12th January 2016) Authors: Taniguchi, Hiroya; Komori, Azusa; Narita, Yukiya; Kadowaki, Shigenori; Ura, Takashi; Andoh, Masashi; Yatabe, Yasushi; Komori, Koji; Kimura, Kenichi; Kinoshita, Takashi; Muro, Kei Journal: Japanese journal of clinical oncology Issue: Volume 46:Number 3(2016:Mar.) Page Start: 228 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗